A federal jury in Wilmington, Del., found that Boston Scientific's Taxus drug-eluting stent and two of the company's bare-metal stents infringe on competitor Cordis' technology. A new jury scheduled to convene in August will determine the amount of damages owed to Cordis, a Johnson & Johnson company, and whether the patent infringement was willful, potentially tripling damages, J&J said in a news release. Boston Scientific said in a news release that it is disappointed in the decision, but there will likely be "significant post-verdict motions and hearings, as well as an appeal of the decision." It was the second victory in recent weeks for Cordis in patent disputes with Boston Scientific. -- by Cinda Becker
Boston Scientific stents found to violate Cordis patents
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.